Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENT001 safety, tolerability, and pharmacokinetics study in moderately to severely active ulcerative colitis
NL-OMON60455Phase 1Completed
- Sponsor
- Enthera Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of Ebrasodebart in autoimmune colitis, sponsored by Enthera Pharmaceuticals. Primary endpoint: Primary endpoint(s). Started Jan 2024; status: completed.
02
Drugs
Ebrasodebart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60455.